Targeted Radionuclide Tumor Therapy

1. Front Matter

   Pages i-xiii

   PDF

2. Introduction to Radionuclide Therapy

   • Jörgen Carlsson, Torgny Stigbrand, Gregory P. Adams

   Pages 1-11

3. Therapeutically Used Targeted Antigens in Radioimmunotherapy

   • Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson

   Pages 13-23

4. EGFR-Family Expression and Implications for Targeted Radionuclide Therapy

   • Jörgen Carlsson

   Pages 25-58

5. Targeting Tumours with Radiolabeled Antibodies

   • Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson

   Pages 59-76

6. Antibody Fragments Produced by Recombinant and Proteolytic Methods

   • Gregory P. Adams

   Pages 77-88

7. Novel Alternative Scaffolds and Their Potential Use for Tumor Targeted Radionuclide Therapy

   • Fredrik Y. Frejd

   Pages 89-116

8. Peptides for Radionuclide Therapy

   • Marion de Jong, Suzanne M. Verwijnen, Monique de Visser, Dik J. Kwekkeboom, Roelf Valkema, Eric P. Krenning

   Pages 117-144

9. Choice of Radionuclides and Radiolabelling Techniques

   • Vladimir Tolmachev

   Pages 145-174

10. High-LET-Emitting Radionuclides for Cancer Therapy

    • George Sgouros

    Pages 175-180

11. Targeted High-LET Therapy of Bone Metastases

    • Øyvind S. Bruland, Dahle Jostein, Dag Rune Olsen, Roy H. Larsen

    Pages 181-194

12. The Auger Effect in Molecular Targeting Therapy

    • Hans Lundqvist, Bo Stenerlöw, Lars Gedda

    Pages 195-214

13. Radiation Induced Cell Deaths

    • David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand

    Pages 215-248

14. Radiation Induced DNA-Damage/Repair and Associated Signaling Pathways

    • Bo Stenerlöw, Lina Ekerljung, Jörgen Carlsson, Johan Lennartsson

    Pages 249-266

15. Radiation Induced DNA Damage Checkpoints

    • David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand

    Pages 267-284

16. Cancer Stem Cells and Radiation

    • David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand

    Pages 285-293

17. Effects of Low Dose-Rate Radiation on Cellular Survival

    • Jörgen Carlsson

    Pages 295-310

18. Bystander Effects and Radionuclide Therapy

    • Kevin M. Prise

    Pages 311-319

19. Enhancing the Efficiency of Targeted Radionuclide Therapy

    • Gregory P. Adams

    Pages 321-328

20. Low Dose Hyper-Radiosensitivity: A Historical Perspective

    • Brian Marples, Sarah A. Krueger, Spencer J. Collis, Michael C. Joiner

    Pages 329-347

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book “Targeted Radionuclide Tumour Therapy – Biological Aspects” was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.

• Cancer Treatment
• Cure vs Palliation
• Monoclonal Antibodies
• Radioimmunotherapy
• Targeted Tumor Therapy
• Tumor
• surgery
• Diagnostic Radiology

From the reviews:

"This book is devoted to understanding the biological aspects of targeted radiotherapy and discusses in depth the various targeting agents as well as the radiopharmaceuticals used in targeted therapy. … Physicians, physicians in training, and physicists who use radionuclide targeted agents in the specialties of radiation oncology, medical oncology, and nuclear medicine are the intended audience. … Overall this is a very informative book for physicians particularly interested in the biological aspects of targeted radiotherapy." (James G. Douglas, Doody’s Review Service, November, 2009)

• Department of Immunology, University of Umea, Umea, Sweden

  Torgny Stigbrand

• Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

  Jörgen Carlsson

• Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA

  Gregory P. Adams

Policies and ethics